Protos Biologics offers a virus‑free delivery platform that uses engineered lipid or polymer nanoparticles to transport CRISPR base‑editing and prime‑editing ribonucleoproteins directly to patient tissues. The system provides transient, non‑integrating expression with modular targeting ligands for tissue‑specific uptake and is designed for GMP‑compatible, scalable manufacturing. It serves biotech, pharmaceutical developers and academic labs developing in‑situ gene‑editing therapeutics.
Funding
Funding not disclosed
Founders
Product
Problem
Current gene‑therapy approaches depend on viral vectors, which present safety concerns such as immunogenicity and insertional mutagenesis, have limited cargo capacity, and involve complex, costly manufacturing processes. These constraints hinder the development of precise, in‑situ genetic corrections for many therapeutic indications.
Solution
Protos Biologics provides a virus‑free therapeutic platform that delivers gene‑editing components directly to patient tissues for precise in‑situ DNA repair. The system employs engineered non‑viral carriers—such as lipid or polymer nanoparticles—to encapsulate CRISPR base‑editing or prime‑editing ribonucleoproteins, enabling transient expression without genomic integration. By eliminating viral capsids, the platform reduces immune responses, simplifies scale‑up, and expands the range of treatable cell types. It incorporates modular targeting ligands or antibody fragments to achieve tissue‑specific delivery, supporting both systemic and localized administration routes. The technology is designed for GMP‑compatible manufacturing and includes an integrated bioinformatics pipeline for edit design, off‑target assessment, and pre‑clinical validation, accelerating the path from discovery to clinical testing.
Target Audience
Primary customers are biotech and pharmaceutical companies developing gene‑editing therapeutics, as well as academic research groups seeking a safe, scalable delivery system for in‑situ genetic correction.
Features
- Engineered lipid/polymer nanoparticle carriers optimized for high‑efficiency delivery of CRISPR RNP complexes
- Transient, non‑integrating expression of base editors or prime editors to minimize off‑target and insertional risks
- Surface‑functionalized ligands and antibody fragments for tissue‑specific targeting and enhanced cellular uptake
- Scalable GMP‑compatible production process with defined particle size distribution and batch‑to‑batch consistency
- Integrated bioinformatics suite for guide‑RNA design, off‑target prediction, and in‑silico safety profiling
- Compatibility with both intravenous and local injection routes, enabling flexible clinical deployment
- Preclinical validation pipeline covering pharmacokinetics, biodistribution, and immunogenicity assessments
- Modular platform architecture allowing rapid adaptation to new genetic targets and disease indications